The IMpower150 trial, comparing carboplatin, paclitaxel and bevacizumab (BCP) with or without atezolizumab (ABCP), included 124 EGFR positive patients.
The study evaluated a neoadjuvant combination of nivolumab, carboplatin and paclitaxel for 3 cycles followed by surgery and adjuvant nivolumab for 1 year in 46 patients with resectable stage IIIA NSCLC.